Drug intelligence / Profile preview

SAT-122

Development stage: Preclinical
Lead developer: Satya Pharma Innovations
Modality: Small Molecules

Overview

SAT-122 is a small molecule inhibitor that disrupts the interaction between RAD51 and BRCA2, key proteins involved in homologous recombination DNA repair. By inhibiting RAD51, SAT-122 aims to sensitize cancer cells—particularly those resistant to PARP inhibitors—to DNA-damaging therapies. The drug is being developed by Satya Pharma Innovations for the treatment of solid tumors, with a focus on overcoming resistance mechanisms in cancers that have become refractory to existing treatments targeting DNA repair pathways[1][2][4].

Other names: RAD51:BRCA2 Disruptor

Targets

RAD51 (RAD51 Recombinase)

Beyond the preview

Go deeper on SAT-122.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAT-122.

Explore the full profile